Prix RespireRx Pharmaceuticals Inc (RSPI)

RespireRx Pharmaceuticals, Inc. engages in the discovery, development and commercialization of innovative pharmaceuticals for the treatment of neurological and psychiatric disorders. The company is headquartered in Glen Rock, New Jersey and currently employs 2 full-time employees. The firm is focused on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (ADHD), recovery from SCI, certain neurological orphan diseases and obstructive sleep apnea (OSA). The firm is developing a pipeline of new and repurposed drug products based on its patent portfolios for two drug platforms: neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or PAMs) GABAA receptors and AMPA-type glutamate receptors, respectively, and pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors.